English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

VaxTyVi® is a plain polysaccharide vaccine based on the capsular polysaccharide Vi (PsVi) from Salmonella Typhi, produced at Finlay Institute. Quantification of PsVi in VaxTyViTM, is a mandatory requirement for final product release and has being made by inhibition ELISA. Considering the disadvantages of this type of ELISA and that recently our group obtained a MAb against PsVi, the aim of this work, was to develop a sandwich ELISA to quantify PsVi in VaxTyViTM. M&M. Using MAb 4G3E11 as the capture and detection, a sandwich ELISA was developed. Limits of detection (LOD) and quantitation (LOQ) were calculated, as well as the interand intra-assay for each point of the standard curve. The PsVi content in six batches of VaxTyViTM was also determined. Results. An eight-point calibration curve with a range from 50 to 0.39 ng/mL of PsVi was obtained with a coefficient of determination (R2) ≥0.99. The LOD and LOQ were 0.59 ng/mL and 1.25 ng/mL respectively, representing at least 1000 times more sensitive than inhibition ELISA. The inter-assay CV was 4–15%, and the intra-assay CVs varied between 3-8 % and 4–9% for intraplate and interplate respectively. The PsVi content in all VaxTyViTM lots were found into the accepted range (±30%). In summary, the proposed sandwich shown to be specific, reproducible and highly sensitive. The assay shown to be suitable for use in the quantitation of PsVi in VaxTyViTM, with great potential to replace the inhibition ELISA, implanted in the Finlay Institute since 2006.

Quantification of polysaccharide Vi in the typhoid vaccine VaxTyViTM by sandwich ELISA using a monoclonal antibody.